We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

FEVR Fevertree Drinks Plc

-4.50 (-0.46%)
Last Updated: 10:59:51
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Fevertree Drinks Plc LSE:FEVR London Ordinary Share GB00BRJ9BJ26 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  -4.50 -0.46% 965.50 34,118 10:59:51
Bid Price Offer Price High Price Low Price Open Price
965.50 970.50 972.50 963.50 970.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Wine & Alcoholic Bev-whsl 364.4M 15.4M 0.1320 73.67 1.13B
Last Trade Time Trade Type Trade Size Trade Price Currency
10:59:52 O 2 965.50 GBX

Fevertree Drinks (FEVR) Latest News

Fevertree Drinks (FEVR) Discussions and Chat

Fevertree Drinks Forums and Chat

Date Time Title Posts
22/7/202411:48FEVER TREE with chart8,676
27/4/202306:22Fevertree Drinks PLC (Fever-Tree)1,966
26/11/202111:18Fevertree - private investor971
26/3/201910:54Fevertree Drinks FY Results 26.03.19 Preview5

Add a New Thread

Fevertree Drinks (FEVR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

Fevertree Drinks (FEVR) Top Chat Posts

Top Posts
Posted at 24/7/2024 09:20 by Fevertree Drinks Daily Update
Fevertree Drinks Plc is listed in the Wine & Alcoholic Bev-whsl sector of the London Stock Exchange with ticker FEVR. The last closing price for Fevertree Drinks was 970p.
Fevertree Drinks currently has 116,686,649 shares in issue. The market capitalisation of Fevertree Drinks is £1,134,777,662.
Fevertree Drinks has a price to earnings ratio (PE ratio) of 73.67.
This morning FEVR shares opened at 970p
Posted at 21/6/2024 09:43 by bamboo2
Carlsberg shares were on course for their largest single-day decline in more than four years on Friday, after the British soft drinks maker Britvic said it had rejected the Danish brewer’s £3.11 billion ($3.9 billion) takeover proposal.

Shares of Carlsberg were down by 8.7% at 09:04 a.m. London time, according to LSEG data. This is the company’s largest single-day share drop since March 12, 2020, when stock fell 8.77%.

Britvic surged by 12.5% on the back of the same news.

This breaking news story is being updated...
Posted at 11/6/2024 00:42 by growthpotential
Need to see some growth in ROW including Australia. Got the in laws coming over next weekend and have just got some ginger ales, raspberry lemonade and Italian blood orange soda in from the Fever-Tree range. Also spoke to someone else at the supermarket till and she says the FEVR drinks are great
Posted at 30/5/2024 09:14 by apad
I first bought FEVR in 2014 and have increased every year in the 10 years since. Trimmed a few times and my net cost is about half the current price. Divis ignored.
My current focus is entirely on the US where they employed americans to manage the company, rather than running it from the UK.
As a result they are rolling out steadily and sensibly through States as if they are different countries, creating appropriate mixers and linking with spirits companies.
They are doing better at surviving the difficult markets in consumer products than a lot of companies with different products and the brand is difficult to attack.
Brands have marketing value that is not represented in the balance sheet but shouldn't be ignored.
It's my second biggest holding so I won't be increasing, but I think now is a good entry opportunity. Negative broker comments and a difficult world is the right time to buy solid companies with a lead over the opposition. Especially when they are moving through a country much richer than the ROW.
Posted at 29/5/2024 19:11 by disc0dave46
CTFair point on price increases.Folks will and have always said this is too pricey on a PE, but it's not on PEG (it's 12m F/cast is only 0.8).It's all about conquering the US - if they can!.Being patient and haven't bought yet as waiting for signs of a breakout above c £12.All the best too.
Posted at 26/3/2024 10:27 by disc0dave46
Hi CTUS up 22%, that's the future.At first glance a bit underwhelming tbh with them missing their revised Rev target for the year of £380m-£390m. But margin as revised at H1 so in the price. Pbt also down 28% so again at first glance doesn't look good.But if they double their EBITDA and they've said 15% margin so if my quick calcs are correct FY24 Rev is looking like c £407m (consensus £395m) that's +12% and ergo pbt will be double at IMO c £45m, eps c 30p to 32p.As posted previously it's not about the short/medium term it's getting those margins back to 2017-18 levels.
Posted at 31/1/2024 08:23 by castleford tiger
AIM so IHT funds in this. I guess.

I hear what has been said but remember I sell the stuff.
It’s very price sensitive and sells on promo but much slower at full retail.
At 30 p for a can of Schp we have noticed people moving back against the 85/90p per bottle.
The gin market is very mature now.
Prices went up 10% last year and U.K. sales did not increase LFL.
Posted at 27/1/2024 21:08 by apad
In these times of highly fluctuating costs, how many years of revenue buys the company is a good metric.
FEVR is about 3.5 years.
Given the potential for growth this is not so expensive.
Amusingly Bioventix is 19 years 😊
Posted at 27/1/2024 10:47 by disc0dave46
Some very large buys over the past few months.Held these years ago and did very well (lucky), never understood the high rating either but went with PEG, which I notice is below 1 again. Forecast eps for FY24 is on a par with 2017 during their significant growth phase, share price then went from £11 to £21......whilst UK growth isn't anywhere near going to be the same as then, the US looks very much like it could be!.Sometimes perceived value on PE alone misses the potential IMO. With revenues at all time highs and still growing despite the macros, getting back to profitability margins pre pandemic and the skys the limit!, just check out their op margins and ROCE pre 2020.
Posted at 16/1/2024 14:14 by philanderer
Liberum upgrades Fevertree on recovery prospects

Liberum has upgraded premium mixer maker Fevertree (FEVR) as a trough in margins indicates a recovery in this year and next.

Analyst Anubhav Malhotra upgraded his recommendation from ‘hold’ to ‘buy’ and increased the target price from £12.00 to £13.00 on the stock, which was trading at £9.98 on Monday.

Malhotra said the company’s strategy ‘has been focused on market share gains against a backdrop of significant input cost inflation over the last two years’.

Margins have ‘troughed̵7; after a 20-percentage point gross margin decline over the last three-and-a-half years, making room for recovery.

‘We see scope for a greater recovery in 2024 and 2025 than consensus expects and therefore move to ‘buy’230; but we note that the top line is likely to remain subdued,’ Malhotra said.

‘Despite the [fact] that ‘bad news’ might not be over, the valuation at 17x 12 months forward consensus embedded value/Ebitda and 28x price/earnings – 40-50% below historic average – looks reasonable.’

Mahotra said that for investors ‘wanting to build a position, now is the time considering the low average daily volume of 265,000’.
Posted at 16/1/2024 10:37 by gipps
Hi Mike yes i am in Fevertree and Distil and hope that this year they both recover to where they were some ago,i really think that they are both on the recovery path.Distil has a couple of big names in this field invested in it and hope that their in put will seriously improve the share price in time.
Fevertree Drinks share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock